KAT5 and breast carcinoma: Some promising HAT inhibitors serve as epi-drugs, such as TIP60-specific inhibitors (TH1834, garcinol, pentamidine, NU9056, and bisubstrate inhibitor A) and multi-HAT inhibitor (MG-149, curcumin, Lys-CoA, and anacardic acid) for the treatment of breast cancer (Table 1).